Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31700253 | 1.00 | GAA (0.58) | GAACYP11B2CYP11B1ALDH1A1CYP1A2 | |
| SCHEMBL5606442 | 0.95 | GAA (0.53) | GAACYP11B2CYP11B1ALDH1A1CYP1A2 | |
| SCHEMBL31500101 | 0.95 | GAA (0.53) | GAACYP11B2CYP11B1ALDH1A1CYP1A2 | |
| SCHEMBL22797004 | 0.89 | CYP11B2 (0.54) | GAACYP11B2CYP11B1ALDH1A1DRD2 | |
| Trifluoroacetic Acid SCHEMBL30547501 | 0.87 | ALDH1A1 (0.50) | GAACYP11B2CYP11B1ALDH1A1CYP1A2 | |
| SCHEMBL30777579 | 0.83 | CYP11B1 (0.60) | GAACYP11B2CYP11B1ALDH1A1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL12494588 | 0.82 | ALDH1A1 (0.45) | GAACYP11B2CYP11B1ALDH1A1CYP1A2 | |
| SCHEMBL30623522 | 0.79 | HTT (0.56) | GAACYP11B2ALDH1A1CYP3A4CHRNB2 | |
| SCHEMBL30441248 | 0.79 | HTT (0.56) | GAACYP11B2ALDH1A1CYP3A4CHRNB2 | |
| SCHEMBL24045800 | 0.79 | CYP11B1 (0.55) | GAACYP11B2CYP11B1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-2231680-B1 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2922841-B1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2014074660-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-7858784-B2 | Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | GAA 1146/4885CYP11B2 3426/4885CYP11B1 3102/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | GAA 2532/4885CYP11B2 753/4885CYP11B1 729/4885 |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | SOD1, TIMCC, TST | GAA 1562/4885CYP11B2 2159/4885CYP11B1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.